Tesamorelin drug interactions: what actually matters

Last updated 2026-07-24

Does tesamorelin interact with other medications through liver enzymes?

No, and this is actually one of the cleaner parts of tesamorelin's safety story. Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue, a 44-amino acid peptide. It's given as a subcutaneous injection and gets broken down by peptidases in the blood and tissue, not by the cytochrome P450 (CYP) enzyme system in the liver that handles most oral drugs. ^[1] That matters because the vast majority of dangerous drug-drug interactions (the ones that show up in interaction checkers with big red warnings) happen when two drugs compete for the same CYP enzyme, or one drug induces or inhibits an enzyme the other one needs. Statins, blood thinners, many antidepressants, and HIV antiretrovirals are full of these. Tesamorelin mostly sidesteps that whole category. This is a big part of why tesamorelin got approved for people with HIV in the first place. Egrifta's phase 3 program specifically included patients on antiretroviral therapy, and the drug didn't show the kind of enzyme-mediated interaction problems that make combining new drugs with protease inhibitors or integrase inhibitors so tricky. A 2024 study looking at tesamorelin efficacy and safety in people with HIV specifically on integrase inhibitor-based regimens found the combination held up without new interaction signals emerging. ^[2] That doesn't mean tesamorelin is interaction-free. It means the interactions that do matter are physiologic, not chemical. Growth hormone axis activation changes blood sugar handling, fluid balance, and possibly how other drugs get processed downstream. Those are covered below.

Can tesamorelin affect blood sugar and diabetes medications?

Yes. This is the single most important interaction to know about, and it's spelled out directly in the drug's clinical trial data. Growth hormone (and by extension, the GHRH that stimulates its release) works against insulin at the cellular level. Increased GH pulses can raise fasting glucose and reduce insulin sensitivity in some patients. ^[3] In the pooled phase 3 trials that got tesamorelin approved, glucose-related adverse events were tracked closely because the study population (people with HIV-associated lipodystrophy) already runs a higher baseline risk of insulin resistance. The pooled analysis of the two double-blind, placebo-controlled phase 3 trials with safety extension data documented changes in glucose parameters as an expected class effect of GHRH stimulation. ^[4] What this means in practice: if you're on metformin, a sulfonylurea, insulin, or any other glucose-lowering medication, your doctor needs to know you're starting tesamorelin. Doses of those medications sometimes need adjusting upward in effect (meaning your diabetes drugs may need to work harder, or dosing may need review) once tesamorelin activates the GH axis. This isn't a reason to avoid tesamorelin outright if you have well-controlled diabetes, but it is a reason for blood glucose monitoring, especially in the first few months. The FDA label for Egrifta is explicit that the drug is not recommended in patients with active malignancy, and that glucose should be monitored given the known relationship between GH stimulation and insulin resistance. Anyone with pre-diabetes or type 2 diabetes should treat this as a real conversation with their prescriber, not a footnote.

Does tesamorelin interact with other growth hormone or peptide therapies?

This is where things get less studied and more about caution than hard data. Tesamorelin's own label warns against combining it with other drugs that affect the GH/IGF-1 axis without medical supervision, because stacking GH-stimulating agents compounds the same physiologic risks (glucose changes, fluid retention, joint or soft tissue symptoms) rather than creating anything new. A lot of people researching tesamorelin are also looking at other peptides, ipamorelin, CJC-1295, sermorelin, and the like, several of which work on the same or overlapping GH-release pathways. Combining a GHRH analogue with a GH secretagogue is common in off-label peptide protocols, but there is no phase 3 trial data on that combination's safety, dosing, or interaction profile. A 2026 review of injectable peptide therapy in sports medicine settings flagged the general lack of rigorous interaction and long-term safety data across the compounded peptide space, tesamorelin included when used outside its approved lane. ^[5] If you're considering a stack, our tesamorelin peptide stack piece and best peptide to stack with tesamorelin article go through what's actually documented versus what's just common practice. A broader 2026 review of therapeutic peptides in orthopaedic applications noted that peptide combination protocols are increasingly common in clinical and off-label settings, but formal interaction data lags far behind adoption. ^[6] The honest answer is: nobody has run a controlled trial combining tesamorelin with another GH secretagogue and reporting on interaction-specific outcomes. Treat any stack as unstudied territory, not as an established regimen.

Is tesamorelin contraindicated with any specific conditions or drugs?

Yes, several. The FDA label lists specific contraindications that function like absolute interaction stops, not dose adjustments. Active malignancy is the clearest one. Because GHRH stimulates GH and downstream IGF-1, and IGF-1 signaling can support tumor growth in susceptible tissue, tesamorelin is not recommended in anyone with active cancer or a history that raises that concern. Pituitary disease, pituitary surgery, radiation to the pituitary region, or head trauma affecting the pituitary/hypothalamic axis are also flagged, since these can affect how predictably the body responds to GHRH stimulation. ^[3] Pregnancy is another firm no. Tesamorelin hasn't been studied in pregnant populations in the phase 3 program (which enrolled adults with HIV-associated lipodystrophy), and the physiologic changes GH stimulation causes aren't ones you want layered onto pregnancy's own metabolic shifts. Anyone who could become pregnant needs this conversation before starting. Hypersensitivity to tesamorelin or mannitol (an excipient in the formulation) is the other clear stop. This is a drug that requires a real medical history review before the first dose, not something to start based on a symptom checklist alone.

Does tesamorelin interact with alcohol or other lifestyle factors?

There's no specific phase 3 data on alcohol interaction with tesamorelin, and no strong theoretical reason to expect a dangerous interaction the way you'd worry about alcohol with, say, benzodiazepines. But alcohol does affect liver function and glucose metabolism, both of which tesamorelin also touches (tesamorelin was specifically studied for its effects on liver fat in HIV-associated NAFLD, showing reduced hepatic fat fraction in a randomized multicenter trial). ^[7] Heavy or regular alcohol use complicates the picture because it's an independent variable affecting the same systems (liver enzymes, glucose, inflammation) that tesamorelin's own trials tracked as outcomes. If you drink regularly, tell your prescriber. It's not a hard stop, but it changes what your bloodwork means and how your provider should interpret changes in liver enzymes or glucose during treatment. Caffeine and typical over-the-counter supplements don't have documented interactions with tesamorelin in the available literature. That's a data gap more than a clean bill of health. Nobody has systematically studied common supplement stacks against GHRH analogue therapy.

What about interactions with HIV antiretroviral drugs specifically?

This is the best-studied interaction question tesamorelin has, because its approved indication is specifically for HIV-associated lipodystrophy, and every phase 3 participant was on some antiretroviral regimen. The pooled phase 3 analysis and its safety extension found the drug maintained its efficacy and safety profile in a population uniformly on ART. ^[4] More recent data has looked specifically at newer regimens. The 2024 study on tesamorelin's efficacy and safety in people with HIV on integrase inhibitors (a drug class that's become the modern first-line ART backbone) found no new interaction concerns specific to that combination. ^[2] This is meaningful because integrase inhibitors themselves carry some metabolic side effects (weight gain being a notable one), and understanding how tesamorelin performs on top of that background was an open question worth specifically testing. The practical takeaway: if you're on antiretroviral therapy, tesamorelin has more real interaction safety data behind it than almost any other peptide drug on the market, specifically because that's the population it was developed and approved for. That's a genuine strength of the evidence base, and it's worth being clear about, since off-label users considering tesamorelin for general fat loss or anti-aging purposes are extrapolating from a dataset built entirely in a different population and indication.

Can tesamorelin be combined with metformin or other insulin-sensitizing drugs safely?

There's no documented contraindication, and the physiologic logic actually points toward metformin being a reasonable co-prescription in patients whose tesamorelin-related glucose changes need managing. But 'no contraindication' isn't the same as 'well studied together.' The trials that established tesamorelin's glucose effects didn't set out to test metformin co-administration as a study arm. What we know is that GHRH stimulation via tesamorelin has a real, measurable effect on glucose parameters in the phase 3 data. ^[4] Managing that with an insulin sensitizer like metformin is standard endocrinology practice, but the decision and monitoring plan should come from whoever is managing your diabetes care, in coordination with whoever prescribes the tesamorelin. This is a case where the right answer is coordination between prescribers, not self-directed stacking. If your primary care doctor manages your metformin and a different provider prescribes tesamorelin, make sure they're actually talking, more than both aware you're on both.

Do injection technique or site choice affect drug interactions?

Not really, but this question comes up enough to address directly. Where you inject tesamorelin (abdomen typically, rotating sites) affects absorption consistency and local skin reactions, not systemic drug interactions. Population pharmacokinetic modeling of tesamorelin in both HIV-infected patients and healthy subjects found predictable absorption and clearance patterns that weren't meaningfully altered by injection site variation within the approved subcutaneous administration method. ^[8] What injection site does affect is local reaction risk (redness, itching, minor swelling) which was one of the more common adverse events in the phase 3 program. That's a tolerability issue, not an interaction issue. If you're new to self-injection, our tesamorelin how to inject and tesamorelin injection sites guides cover technique in detail. One thing that is a genuine consideration: injecting into scar tissue, active dorsocervical fat pads (the 'buffalo hump' some HIV patients develop), or areas with poor circulation can affect how consistently the drug is absorbed, which indirectly affects how predictable its glucose and IGF-1 effects are. A post hoc analysis of the phase 3 trial specifically looked at outcomes in patients with and without dorsocervical fat and found the drug's core efficacy held across both groups. ^[9]

Does tesamorelin interact differently in women versus men?

The approved phase 3 trials for Egrifta enrolled a population that skewed heavily male, reflecting HIV-associated lipodystrophy demographics at the time of the studies. This is a real limitation of the interaction and safety data, not a reason to assume women face specific risks that men don't. Sex-specific interaction data is thin across the board for tesamorelin. What's known about GH axis physiology more broadly suggests estrogen status affects GH sensitivity and IGF-1 response, which is a legitimate consideration for anyone prescribing across sexes, but it hasn't been isolated as a specific interaction concern in tesamorelin's own trial data. If you want the fuller picture on sex-specific evidence gaps, see can women take tesamorelin peptide. Pregnancy and hormonal contraceptive interactions specifically haven't been studied in controlled trials. That's a gap worth naming plainly rather than glossing over.

What monitoring should happen when starting tesamorelin alongside other medications?

At minimum: baseline and follow-up glucose or HbA1c, especially if you're on any diabetes medication or have risk factors for insulin resistance. IGF-1 levels are also typically tracked, since that's the downstream marker of GHRH activity and helps a prescriber judge whether dosing is appropriately calibrated. ^[3] Liver enzymes are worth tracking if you're also being monitored for HIV-associated fatty liver disease, since tesamorelin was specifically studied for hepatic fat reduction in that population and liver enzyme improvement tracked with visceral fat loss in trial data. ^[10] If you're on hepatically cleared medications for unrelated conditions, changes in liver fat and function over a treatment course are a reasonable thing for your prescriber to keep an eye on, even though this isn't a classic 'interaction' in the enzyme-competition sense. A table of what gets checked and why: | Marker | Why it's tracked with tesamorelin | Relevant if you're also on |

Where does provider-reviewed sourcing fit into managing interaction risk?

A drug interaction checker is only as good as the medication list you give it, and tesamorelin's real risks (glucose shifts, contraindications around malignancy and pituitary history, unstudied peptide stacking) require an actual clinician reviewing your full history, more than a database lookup. This is exactly the gap a provider-reviewed pathway is built to close: a prescriber who checks your medication list, orders baseline labs, and follows up on glucose and IGF-1 rather than leaving you to self-monitor. Tesamorelin Co's provider-reviewed pathway connects patients with clinicians who screen for these exact issues before a prescription goes out, and prescriptions are filled through a licensed pharmacy partner, not compounded or manufactured by Tesamorelin Co itself. If cost is part of your decision-making around whether to pursue the approved route, tesamorelin cost breaks down what that actually looks like. The bottom line on interactions: tesamorelin's chemical interaction profile is genuinely clean by pharmaceutical standards, but its physiologic effects on glucose, the GH/IGF-1 axis, and liver metabolism mean it still needs a real medical relationship behind it, more than a check against a drug interaction app.

Frequently asked questions

Does tesamorelin interact with metformin?

There's no known contraindication. Tesamorelin can raise blood glucose through GH axis stimulation, and metformin is a standard tool for managing that, but the combination hasn't been formally studied as a trial arm. Coordinate between whoever prescribes each medication and monitor glucose regularly.

Can I take tesamorelin with insulin?

There's no absolute contraindication, but tesamorelin's known effect of raising blood glucose and reducing insulin sensitivity means insulin dosing may need review after starting. This requires active monitoring by your prescriber, not a fixed answer, since individual glucose response varies.

Is tesamorelin safe to combine with other peptides like ipamorelin or CJC-1295?

No controlled trial has tested these combinations for safety or interaction risk. Both work on overlapping GH-release pathways, so stacking compounds the same physiologic effects (glucose changes, fluid retention) rather than adding something new. Treat any stack as unstudied, off-label territory.

Does tesamorelin interact with HIV antiretroviral drugs?

Tesamorelin's phase 3 trials and later studies were conducted in populations on antiretroviral therapy, including a 2024 study specifically on integrase inhibitor regimens that found no new interaction concerns. This is actually tesamorelin's best-documented interaction category since its approved indication is HIV-associated lipodystrophy.

Who should not take tesamorelin because of contraindications?

People with active malignancy, a history of pituitary disease or pituitary radiation/surgery, pregnancy, or hypersensitivity to tesamorelin or mannitol should not take it. These are firm contraindications from the FDA label, not relative cautions, and require disclosure before any prescription.

Does alcohol interact with tesamorelin?

There's no specific trial data on alcohol interaction, and no strong pharmacologic reason to expect danger. But alcohol affects liver function and glucose metabolism, the same systems tesamorelin's own studies track, so regular drinking is worth disclosing to your prescriber for accurate lab interpretation.

Can tesamorelin affect thyroid medication?

There's no documented interaction between tesamorelin and thyroid hormone replacement in the available trial data. GH axis activity and thyroid function are physiologically connected in general endocrinology, but tesamorelin's own studies haven't isolated this as a specific interaction concern.

Does tesamorelin interact with blood pressure medications?

No specific interaction is documented in tesamorelin's trial data. Fluid retention is a known GH-axis effect worth watching if you're on medications sensitive to volume status, but this hasn't been flagged as a formal drug interaction in the approved labeling or phase 3 studies.

Is it safe to take tesamorelin while pregnant or breastfeeding?

No. Tesamorelin hasn't been studied in pregnant or breastfeeding populations, and pregnancy is listed as a condition where it's not recommended. The phase 3 program that led to FDA approval didn't enroll pregnant participants, so there's no safety data to rely on.

Does injection site matter for how tesamorelin interacts with other drugs?

No, injection site affects absorption consistency and local skin reactions, not systemic drug interactions. Population pharmacokinetic data shows predictable clearance regardless of site within standard subcutaneous administration, though rotating sites and avoiding scar tissue helps keep dosing consistent.

Can tesamorelin be combined with statins or cholesterol medications?

No specific interaction is documented. Tesamorelin doesn't rely on the CYP enzyme pathways that most statins use, so the classic enzyme-competition interaction risk is low. Still, disclose all medications to your prescriber since lipid changes are also tracked as part of tesamorelin's own metabolic monitoring.

What labs should be checked before combining tesamorelin with other medications?

Baseline fasting glucose or HbA1c, IGF-1, and liver enzymes are standard, especially if you're on diabetes medications or being monitored for fatty liver. These catch tesamorelin's real physiologic interactions (glucose shifts, GH axis activation) since it lacks classic enzyme-based interaction flags.

Sources

1. Nature Reviews Drug Discovery, Tesamorelin (2011): Tesamorelin is a synthetic GHRH analogue peptide that is metabolized via peptidase activity rather than hepatic CYP enzymes.
2. AIDS (London), Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (2024): A 2024 study found no new interaction concerns when tesamorelin was used alongside integrase inhibitor-based antiretroviral regimens.
3. J Clin Endocrinol Metab, Approach to the Patient With Lipodystrophy (2022): GH axis stimulation is associated with reduced insulin sensitivity and glucose changes requiring monitoring, and contraindications include pituitary disease history and active malignancy.
4. J Clin Endocrinol Metab, pooled phase 3 tesamorelin trials with safety extension (2010): Pooled phase 3 double-blind placebo-controlled trials with safety extension data tracked glucose parameter changes as an expected effect of tesamorelin's GHRH mechanism.
5. American Journal of Sports Medicine, Injectable Peptide Therapy: A Primer (2026): A 2026 review noted the general lack of rigorous long-term safety and interaction data across compounded injectable peptide protocols.
6. JAAOS Global Research & Reviews, Therapeutic Peptides in Orthopaedics (2026): Peptide combination protocols are increasingly common in clinical and off-label use, but formal interaction data lags behind adoption.
7. The Lancet HIV, Effects of tesamorelin on NAFLD in HIV (2019): A randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat fraction in HIV-associated NAFLD.
8. Clinical Pharmacokinetics, Population pharmacokinetic analysis of tesamorelin (2015): Population pharmacokinetic modeling found predictable absorption and clearance of tesamorelin in both HIV-infected patients and healthy subjects.
9. Journal of Clinical and Translational Science, tesamorelin in patients with and without dorsocervical fat (2023): A post hoc analysis of the phase 3 trial found tesamorelin's efficacy held across patients with and without dorsocervical fat pads.
10. AIDS (London), Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (2017): Visceral fat reduction from tesamorelin correlated with improved liver enzyme levels in HIV patients.